Clinical Implications of a New DDX58 Pathogenic Variant That Causes Lupus Nephritis due to RIG-I Hyperactivation.

Autor:	Peng J; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, People's Republic of China.; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China., Wang Y; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, People's Republic of China.; Life Sciences Institute, Zhejiang University, Hangzhou, People's Republic of China., Han X; Life Sciences Institute, Zhejiang University, Hangzhou, People's Republic of China., Zhang C; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China., Chen X; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, People's Republic of China., Jin Y; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China., Yang Z; Life Sciences Institute, Zhejiang University, Hangzhou, People's Republic of China., An Y; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China., Zhang J; Life Sciences Institute, Zhejiang University, Hangzhou, People's Republic of China., Liu Z; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China., Chen Y; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China., Gao E; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China., Zhang Y; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China., Xu F; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China., Zheng C; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China., Zhou Q; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, People's Republic of China.; Life Sciences Institute, Zhejiang University, Hangzhou, People's Republic of China., Liu Z; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, People's Republic of China.; National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China.
Jazyk:	angličtina
Zdroj:	Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2023 Feb 01; Vol. 34 (2), pp. 258-272. Date of Electronic Publication: 2022 Oct 19.
DOI:	10.1681/ASN.2022040477
Abstrakt:	Background: Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus, with heterogeneous phenotypes and different responses to therapy. Identifying genetic causes of LN can facilitate more individual treatment strategies. Methods: We performed whole-exome sequencing in a cohort of Chinese patients with LN and identified variants of a disease-causing gene. Extensive biochemical, immunologic, and functional analyses assessed the effect of the variant on type I IFN signaling. We further investigated the effectiveness of targeted therapy using single-cell RNA sequencing. Results: We identified a novel DDX58 pathogenic variant, R109C, in five unrelated families with LN. The DDX58 R109C variant is a gain-of-function mutation, elevating type I IFN signaling due to reduced autoinhibition, which leads to RIG-I hyperactivation, increased RIG-I K63 ubiquitination, and MAVS aggregation. Transcriptome analysis revealed an increased IFN signature in patient monocytes. Initiation of JAK inhibitor therapy (baricitinib 2 mg/d) effectively suppressed the IFN signal in one patient. Conclusions: A novel DDX58 R109C variant that can cause LN connects IFNopathy and LN, suggesting targeted therapy on the basis of pathogenicity. Podcast: This article contains a podcast at. (Copyright © 2022 by the American Society of Nephrology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu